



23 October 2019

## ASX Announcement

### Penthrox<sup>®</sup> is launched in Italy

Medical Developments International Ltd (ASX: MVP) is delighted to announce that Penthrox has been launched in Italy.

MVP CEO Mr. John Sharman said, "We are delighted to finally launch Penthrox in the important European market of Italy. There has been a number of clinical studies completed in preparation for the launch of Penthrox in Italy. In particular, a study of 272 trauma patients in 15 Italian emergency units ("MEDITA"), showed that Penthrox was SUPERIOR to Standard of Care, including Opioids, for adult trauma pain patients in Italy."

Mr. Sharman continued "The launch of Penthrox in Italy will trigger another milestone payment from our partner Mundipharma of US\$2million which is expected during 2020. Penthrox is now well placed to develop into a leading trauma pain medication in Italy and throughout Europe."

Ms. Maya Marescotti of Mundipharma in Europe said: "We are delighted to have launched Penthrox in Italy, to help provide fast and effective relief for adult patients experiencing trauma pain. We see this inhaled analgesic as an important medication for trauma patients here and throughout Europe and we look forward to our continued collaboration with MDI."

Enquiries:

David Williams  
Chairman  
Medical Developments International Ltd  
+61 (0) 414 383 593

John Sharman  
Chief Executive Officer  
Medical Developments International Ltd  
+61 (3) 9547 1888



### **About Pentrox®**

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 40 years in Australia with excess of 5.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

### **About Medical Developments International Ltd**

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast-acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

### **About the Mundipharma network**

Mundipharma is a global network of privately-owned independent associated companies whose purpose is to move medicine forward. With a high performing and learning organisation that strives for innovation and commercial excellence through partnerships, we successfully transformed and diversified our European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as Diabetes, Respiratory, Oncology, Pain and Biosimilars. For more information please visit: [www.mundipharma.com](http://www.mundipharma.com).